ClinicalTrials.gg
CompletedNCT05674929Updated May 22, 2026Results posted

An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

A Phase 2 interventional study of BPL-003 in Alcohol Use Disorder, sponsored by Beckley Psytech Limited. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Alcoholism with a site in United Kingdom — 8 open to participants now, 9 under way, 2 of them phase 3. Alcoholism · United Kingdom.

Enrollment
27th of 29
13 · median 56
Started
2023
with 2 others
Phase 2
2 of 33
none open now
Registered
24th of 33
by date
Lead sponsor
1 of 33
Beckley Psytech Limited

Among the 33 studies in Alcoholism with a site in United Kingdom, this one is the 27th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 2, and was the 24th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 33 studies in Alcoholism with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Alcoholism with a site in United Kingdom, or all of them as a file.
02

Study summary

An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.

Read the detailed description

Approximately 12 eligible participants will be receive a single dose of BPL-003, given intranasally, with 12 weeks of follow-up assessments. Psychological support will be given before, during and after dosing

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give .
  2. Age 18 to 64 years at Screening.
  3. Diagnosed with moderate to severe AUD.
  4. Minimum of 4 heavy drinking days in the 28 days before Screening.
  5. No more than 14 days have elapsed since the last HDD or completion of detoxification, with no HDD in the 72 hours prior to dosing and no alcohol at all in the 24 hours prior to dosing
  6. Willing to abstain from using recreational drugs from Screening until end of the study
  7. Willing to abstain from smoking during their time in the clinic on the day of dosing.
  8. Willing to refrain from psychedelic drug use from Screening until the end of the study.
  9. Living in stable/secure accommodation in the community.
  10. In possession of a personal mobile phone and able to nominate at least one locator individual (eg, a family member, friend, or recovery mentor), with a verifiable address and a telephone number to assist with the arrangement of follow-up appointments.

Exclusion criteria

Exclusion Criteria:

  1. Personal or first-degree family history of schizophrenia, bipolar disorder, psychotic disorder, delusional disorder, paranoid disorder or schizoaffective disorder.
  2. Any major psychiatric disorders, with the exception of mild or moderate anxiety and/or depression.
  3. A clinical diagnosis of post-traumatic stress disorder.
  4. Suicide ideation or behaviour or self-injurious behaviours within the 12 months before screening
  5. Regular use of or dependence on other drugs other than caffeine or nicotine.
  6. Any self-reported use of psychedelic compounds in the past 6 months.
  7. History of seizures.
  8. Patients who are exhibiting any signs of alcohol withdrawal on dosing day.
  9. Positive for alcohol on dosing day.
  10. Positive urine drug screen for illicit drugs or drugs of abuse.
  11. Any nasal obstruction, blockage, or symptoms of congestion.
  12. Any personal or family history of malignant hyperthermia.
  13. Patients with an uncontrolled cardiovascular disorder that, in the opinion of the Investigator, may interfere with the interpretation of study results or constitute a health risk for the patient if he/she takes part in the study.
  14. Uncontrolled or insulin-dependent diabetes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    BPL-003 arm

    Drug: BPL-003

Interventions

  • A single dose administered intranasally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events

    The number (%) of participants with at least one treatment-emergent adverse event is presented. More detailed information is provided in the dedicated 'Adverse Events' section

    Time frame: Up to 12 weeks

  2. Percentage of Participants With Clinically Significant Abnormal Laboratory Tests

    The number (%) of participants with any clinically significant abnormal laboratory tests (routine haematology, clinical chemistry and coagulation) is presented

    Time frame: Up to 12 weeks

  3. Percentage of Participants With Clinically Significant Abnormal Vital Signs

    The number (%) of participants with any clinically significant abnormal vital signs (blood pressure, heart rate and temperature) result is presented

    Time frame: Up to 12 weeks

  4. Number of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS Score

    The C-SSRS was performed at screening, on Day 0 (dosing day), and on Days 1, 7, and 84 post-dose. Participants were counted if they answered 'yes' to any question. At baseline, the C-SSRS assessed the worst-point suicidal ideation experienced during the participant's lifetime. Beyond baseline, suicidal ideation and behaviour since last visit was assessed.

    Time frame: Up to 12 weeks

  5. Time to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ)

    The RDQ was a brief assessment scale to ensure that ahead of discharge after BPL-003 dosing, participants: * Were fully responsive, aware of their surroundings, and reacted adequately * The acute psychedelic effects of the drug had completely subsided * Were fully orientated (name, location, time) * Had normal (or only slightly elevated) blood pressure and pulse rate, and normal breathing frequency and body temperature * Had a stable gate, normal muscle coordination, and could walk safely * Had only mild to moderate potential side affects that did not need to be medically monitored * Had no acute suicidal ideations or suicidal intentions * Possible distress or feelings of overwhelm had sufficiently subsided and the participant felt safe to be discharged. Readiness for discharge was assessed at 90 minutes post-dose and then every 30 minutes until the participant was deemed ready for discharge (eg, the answer was 'yes' to all of the above items).

    Time frame: 1 Day

  6. Percentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ)

    The occurrence and (if applicable) frequency, emotional valence, and functional impact of any reactivation events was determined. To determine if reactivation had occurred, participants were asked if they had any flashbacks or recurrence of any effects of the study drug experience.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Effects on the Mystical Experience Questionnaire (MEQ-30)

    The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence of space and time, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. The total MEQ-30 score is presented. The higher the score, the greater the mystical experience. A total score of ≥3 was considered to be a significant mystical experience.

    Time frame: 1 Day

  2. Effects on the Ego Dissolution Inventory (EDI)

    The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Higher scores are indicative of more intense ego dissolution. In practice, this means participants with higher scores could have a reduced sense of having a distinct, separate self; greater feelings of unity with the environment or universe; a loss of self-referential thoughts or identity; or altered boundaries between 'self' and 'other'. A 'total EDI score' was calculated for each participant as the average of their individual-item scores. The total EDI score is presented.

    Time frame: 1 Day

  3. Percentage of Participants With a Complete Mystical Experience Using the MEQ-30

    The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. A complete mystical experience was defined as reaching or exceeding a score of 3 on all four sub-domains (mystical, positive mood, transcendence of time and space, and ineffability) of the MEQ-30 scale.

    Time frame: 1 Day

  4. Percentage of Participants Experiencing an Ego Dissolution Using the EDI

    The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Participants were classed as experiencing an ego dissolution if they had a total score of \>50.0 out of 100 on the EDI scale.

    Time frame: 1 Day

  5. Description of the BPL-003 Subjective Experience Data, From a Qualitative Interview

    After BPL-003 dosing, participants had the option to participate in a one-to-one guided interview with independent researchers trained in microphenomenology methods to describe their psychedelic experience. Temporal aspects of drug effects (e.g., sensory, cognitive, metacognitive, and sense of self/other/connectedness) were elicited through open-ended interview questions.

    Time frame: Interviews were conducted approximately 2 hours after dosing

  6. Feedback From Therapists on the Frequency and Duration of Psychotherapy Sessions, Therapy Manual and Overall Therapy Model

    Key themes from qualitative feedback on the treatment model was sought from therapists on frequency and duration of psychotherapy sessions, implementation of therapy manual, and overall therapy model. Feedback was obtained in a qualitative interview with each therapist after each participant's last integration session (between Day 15 and Day 42).

    Time frame: 1 Day

  7. Semi-structured Interview to Assess Psychological Changes Following BPL-003 Treatment

    After BPL-003 dosing, participants had the option to participate in a semi-structured interview. The interviews were topic-guided, qualitative interviews to understand psychological changes shortly after dosing on Day 1, and on Day 84.

    Time frame: Up to 12 weeks

Other outcomes

  1. Timeline Follow-Back (TLFB) Interview to Assess the Percentage of Abstinent Days (PAD)

    Using the TLFB interview, the PAD in the 85 days before Day -3 (or start of detox) vs the PAD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.

    Time frame: Up to 12 weeks

  2. TLFB Interview to Assess the Percentage of Heavy Drinking Days (PHDD)

    Using the TLFB interview, the PHDD in the 85 days before Day -3 (or start of detox) vs PHDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.

    Time frame: Up to 12 weeks

  3. TLFB Interview to Assess the Percentage of Drinking Days (PDD)

    Using the TLFB interview, the PDD in the 85 days before Day -3 (or start of detox) vs PDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.

    Time frame: Up to 12 weeks

07

Results

Posted May 22, 2026

Participant flow

Participants were recruited to the study between 29 March 2023 and 02 July 2024 from community treatment services for addiction, or by community advertisement.

Participant flow — Overall Study
MilestoneBPL-003 Arm
Started13
Completed12
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events

The number (%) of participants with at least one treatment-emergent adverse event is presented. More detailed information is provided in the dedicated 'Adverse Events' section

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Treatment Emergent Adverse Events
ParticipantsBPL-003 Arm
Percentage of Participants With Treatment Emergent Adverse Events11
PrimaryPercentage of Participants With Clinically Significant Abnormal Laboratory Tests

The number (%) of participants with any clinically significant abnormal laboratory tests (routine haematology, clinical chemistry and coagulation) is presented

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Clinically Significant Abnormal Laboratory Tests
ParticipantsBPL-003 Arm
Percentage of Participants With Clinically Significant Abnormal Laboratory Tests0
PrimaryPercentage of Participants With Clinically Significant Abnormal Vital Signs

The number (%) of participants with any clinically significant abnormal vital signs (blood pressure, heart rate and temperature) result is presented

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Clinically Significant Abnormal Vital Signs
ParticipantsBPL-003 Arm
Percentage of Participants With Clinically Significant Abnormal Vital Signs4
PrimaryNumber of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS Score

The C-SSRS was performed at screening, on Day 0 (dosing day), and on Days 1, 7, and 84 post-dose. Participants were counted if they answered 'yes' to any question. At baseline, the C-SSRS assessed the worst-point suicidal ideation experienced during the participant's lifetime. Beyond baseline, suicidal ideation and behaviour since last visit was assessed.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS Score
ParticipantsBPL-003 Arm
Number of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS Score1
PrimaryTime to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ)

The RDQ was a brief assessment scale to ensure that ahead of discharge after BPL-003 dosing, participants: * Were fully responsive, aware of their surroundings, and reacted adequately * The acute psychedelic effects of the drug had completely subsided * Were fully orientated (name, location, time) * Had normal (or only slightly elevated) blood pressure and pulse rate, and normal breathing frequency and body temperature * Had a stable gate, normal muscle coordination, and could walk safely * Had only mild to moderate potential side affects that did not need to be medically monitored * Had no acute suicidal ideations or suicidal intentions * Possible distress or feelings of overwhelm had sufficiently subsided and the participant felt safe to be discharged. Readiness for discharge was assessed at 90 minutes post-dose and then every 30 minutes until the participant was deemed ready for discharge (eg, the answer was 'yes' to all of the above items).

Time frame:
1 Day
Reported as:
Median · Hours
Time to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ)
HoursBPL-003 Arm
Time to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ)2.1 (1.4 to 3.8)
PrimaryPercentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ)

The occurrence and (if applicable) frequency, emotional valence, and functional impact of any reactivation events was determined. To determine if reactivation had occurred, participants were asked if they had any flashbacks or recurrence of any effects of the study drug experience.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ)
ParticipantsBPL-003 Arm
Percentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ)0
SecondaryEffects on the Mystical Experience Questionnaire (MEQ-30)

The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence of space and time, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. The total MEQ-30 score is presented. The higher the score, the greater the mystical experience. A total score of ≥3 was considered to be a significant mystical experience.

Time frame:
1 Day
Reported as:
Median · score on 0 to 5 scale
Effects on the Mystical Experience Questionnaire (MEQ-30)
score on 0 to 5 scaleBPL-003 Arm
Total MEQ-30 score3.07 (0.63 to 4.67)
Mystical subdomain score2.60 (0.40 to 4.60)
Positive mood subdomain score3.50 (1.00 to 4.67)
Transcendence of time and space subdomain score3.92 (0.67 to 5.00)
Ineffability subdomain score3.84 (1.00 to 5.00)
SecondaryEffects on the Ego Dissolution Inventory (EDI)

The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Higher scores are indicative of more intense ego dissolution. In practice, this means participants with higher scores could have a reduced sense of having a distinct, separate self; greater feelings of unity with the environment or universe; a loss of self-referential thoughts or identity; or altered boundaries between 'self' and 'other'. A 'total EDI score' was calculated for each participant as the average of their individual-item scores. The total EDI score is presented.

Time frame:
1 Day
Reported as:
Median · Total score on 0 to 100 scale
Effects on the Ego Dissolution Inventory (EDI)
Total score on 0 to 100 scaleBPL-003 Arm
Effects on the Ego Dissolution Inventory (EDI)52.4 (6 to 82)
SecondaryPercentage of Participants With a Complete Mystical Experience Using the MEQ-30

The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. A complete mystical experience was defined as reaching or exceeding a score of 3 on all four sub-domains (mystical, positive mood, transcendence of time and space, and ineffability) of the MEQ-30 scale.

Time frame:
1 Day
Reported as:
Count of participants · Participants
Percentage of Participants With a Complete Mystical Experience Using the MEQ-30
ParticipantsBPL-003 Arm
Percentage of Participants With a Complete Mystical Experience Using the MEQ-304
SecondaryPercentage of Participants Experiencing an Ego Dissolution Using the EDI

The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Participants were classed as experiencing an ego dissolution if they had a total score of \>50.0 out of 100 on the EDI scale.

Time frame:
1 Day
Reported as:
Count of participants · Participants
Percentage of Participants Experiencing an Ego Dissolution Using the EDI
ParticipantsBPL-003 Arm
Percentage of Participants Experiencing an Ego Dissolution Using the EDI7
SecondaryDescription of the BPL-003 Subjective Experience Data, From a Qualitative Interview

After BPL-003 dosing, participants had the option to participate in a one-to-one guided interview with independent researchers trained in microphenomenology methods to describe their psychedelic experience. Temporal aspects of drug effects (e.g., sensory, cognitive, metacognitive, and sense of self/other/connectedness) were elicited through open-ended interview questions.

Time frame:
Interviews were conducted approximately 2 hours after dosing
Reported as:
Count of participants · Participants
Description of the BPL-003 Subjective Experience Data, From a Qualitative Interview
ParticipantsBPL-003 Arm
Sensory domain [body effect]: unusual physical sensations5
Sensory domain [body effect]: Not feeling the body5
Sensory domain [time perception]: lost sense of time or time felt shorter/longer8
Cognition domain [insight/meaning]: Insights, personal meaning at the peak of the experience6
Cognition domain [control/letting go]: Actively doing something (e.g., asking existential questions)7
Metacognition domain [meta-awareness of emotions]: Thoughts about feelings5
Metacognition domain [monitoring own thoughts]: Tracking content and frequency of thoughts6
Metacognition domain [metacognitive control]: Emotional regulation7
Self/Others/Connectedness domain [cognitive self-consciousness]: No/minimal sense of self5
Self/Others/Connectedness domain [spatial self-consciousness]: Loss of sense of space7
SecondaryFeedback From Therapists on the Frequency and Duration of Psychotherapy Sessions, Therapy Manual and Overall Therapy Model

Key themes from qualitative feedback on the treatment model was sought from therapists on frequency and duration of psychotherapy sessions, implementation of therapy manual, and overall therapy model. Feedback was obtained in a qualitative interview with each therapist after each participant's last integration session (between Day 15 and Day 42).

Time frame:
1 Day
Reported as:
Count of participants · Participants
Feedback From Therapists on the Frequency and Duration of Psychotherapy Sessions, Therapy Manual and Overall Therapy Model
ParticipantsBPL-003 Arm
A shift in perspective, inducing reflection and disruption of habitual processes4
Increases in self-compassion and acceptance4
Reappraisal of identity, core beliefs and values3
Facing fears and overcoming adversity3
Other pre-specifiedTimeline Follow-Back (TLFB) Interview to Assess the Percentage of Abstinent Days (PAD)

Using the TLFB interview, the PAD in the 85 days before Day -3 (or start of detox) vs the PAD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.

Time frame:
Up to 12 weeks
Reported as:
Mean · % of abstinent days
Timeline Follow-Back (TLFB) Interview to Assess the Percentage of Abstinent Days (PAD)
% of abstinent daysBPL-003 Arm
PAD 85 days prior to Day -333.15 ± 22.80
PAD at Day 1489.88 ± 24.26
PAD at Day 2888.69 ± 20.93
PAD at Day 5683.78 ± 25.56
PAD at Day 8480.84 ± 28.23
Other pre-specifiedTLFB Interview to Assess the Percentage of Heavy Drinking Days (PHDD)

Using the TLFB interview, the PHDD in the 85 days before Day -3 (or start of detox) vs PHDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.

Time frame:
Up to 12 weeks
Reported as:
Mean · % of heavy drinking days
TLFB Interview to Assess the Percentage of Heavy Drinking Days (PHDD)
% of heavy drinking daysBPL-003 Arm
PHDD 85 days prior to Day -356.24 ± 26.39
PHDD at Day 146.55 ± 18.39
PHDD at Day 288.04 ± 17.70
PHDD at Day 5611.31 ± 21.28
PHDD at Day 8413.19 ± 21.84
Other pre-specifiedTLFB Interview to Assess the Percentage of Drinking Days (PDD)

Using the TLFB interview, the PDD in the 85 days before Day -3 (or start of detox) vs PDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.

Time frame:
Up to 12 weeks
Reported as:
Mean · % of drinking days
TLFB Interview to Assess the Percentage of Drinking Days (PDD)
% of drinking daysBPL-003 Arm
PDD 85 days prior to Day -366.85 ± 22.80
PDD at Day 1410.12 ± 24.26
PDD at Day 2811.31 ± 20.93
PDD at Day 5616.22 ± 25.56
PDD at Day 8419.16 ± 28.23
SecondarySemi-structured Interview to Assess Psychological Changes Following BPL-003 Treatment

After BPL-003 dosing, participants had the option to participate in a semi-structured interview. The interviews were topic-guided, qualitative interviews to understand psychological changes shortly after dosing on Day 1, and on Day 84.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Semi-structured Interview to Assess Psychological Changes Following BPL-003 Treatment
ParticipantsBPL-003 Arm
Day 1: Reset, release, or rebirth experience6
Day 1: Increased acceptance, improved emotional processing and connection5
Day 84: Reappraisal of self and relationship with alcohol8
Day 84: Improved awareness, cognitive flexibility, and acceptance6
Day 84: Increased self-compassion, improved relationships, and connections7
Day 84: Improved wellbeing, sleep, and energy levels6

Adverse events

Collected over Treatment-emergent adverse events were recorded throughout the study (from informed consent until end of follow-up, up to 16 weeks overall). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BPL-003 Arm0/13 (0%)0/13 (0%)11/13 (84.6%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventBPL-003 Arm
Administration site painGeneral disorders4/13
Blood pressure increasedInvestigations4/13
NightmarePsychiatric disorders2/13
FlashbackPsychiatric disorders2/13
VomitingGastrointestinal disorders2/13
DissociationPsychiatric disorders1/13
Sleep disorderPsychiatric disorders1/13
AgitationPsychiatric disorders1/13
AnxietyPsychiatric disorders1/13
Depersonalisation/derealisation disorderPsychiatric disorders1/13

Baseline characteristics

Data from all enrolled participants is presented.

Age, Continuous
Age, Continuous(Years)BPL-003 Arm
Mean49.3 ± 10.77
Sex: Female, Male
Sex: Female, Male(Participants)BPL-003 Arm
Female3
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BPL-003 Arm
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race1
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BPL-003 Arm
Hispanic or Latino1
Not Hispanic or Latino12
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)BPL-003 Arm
United Kingdom13
Number of participants with any lifetime suicidal ideation or behaviour based on C-SSRS score
Number of participants with any lifetime suicidal ideation or behaviour based on C-SSRS score(Participants)BPL-003 Arm
Count of participants3
08

Study locations

2 sites
  • Clerkenwell Health
    London, W1G 8DR, United Kingdom
  • King's College London
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Oct 2024, 16 months.

Results were first posted in May 2026, 1 year 7 months after primary completion.

Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Jan 9, 2023
StartActual
May 30, 2023
Primary completionActual
Oct 2, 2024
CompletionActual
Oct 2, 2024
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05674929
Responsible party
Sponsor
First posted
Jan 9, 2023
Start date
May 30, 2023
Primary completion
Oct 2, 2024
Completion
Oct 2, 2024
Results posted
May 22, 2026
Last update
May 22, 2026

Study contacts

Kevin Craig, M.D.
study director · Beckley Psytech Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPL-003

Start the discussion